Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications

J Clin Oncol. 2012 Feb 1;30(4):e41-4. doi: 10.1200/JCO.2011.37.9289. Epub 2011 Dec 19.

Authors

Laetitia Dahan¹, Joseph Ciccolini, Alexandre Evrard, Litaty Mbatchi, Jack Tibbitts, Pauline Ries, Emmanuelle Norguet, Cedric Mercier, Athanassios Iliadis, L'Houcine Ouafik, Bruno Lacarelle, Jean-Francois Seitz

Affiliation

¹ La Timone University Hospital of Marseille, Aix-Marseille Univ, CRO2 UMR 911, Marseille, France.

PMID: 22184401
DOI: 10.1200/JCO.2011.37.9289

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bevacizumab
Camptothecin / administration & dosage
Camptothecin / adverse effects
Camptothecin / analogs & derivatives
Capecitabine
Colorectal Neoplasms / drug therapy*
Death, Sudden / etiology*
Deoxycytidine / administration & dosage
Deoxycytidine / adverse effects
Deoxycytidine / analogs & derivatives
Fluorouracil / administration & dosage
Fluorouracil / adverse effects
Fluorouracil / analogs & derivatives
Humans
Irinotecan
Male
Middle Aged

Substances

Antibodies, Monoclonal, Humanized
Deoxycytidine
Bevacizumab
Capecitabine
Irinotecan
Fluorouracil
Camptothecin